title: HIV-1 Env vaccine comprised of electroporated DNA and protein co-administered with Talabostat.
abstract: Selection of potent yet low reactogenic adjuvants for protein immunization is important for HIV-1 vaccine development. Immunogenicity of electroporated DNA (HIV env) and recombinant gp120, administered with either QS-21 or the orally administered immunomodulator, Talabostat, was evaluated in BALB/c mice. Electroporation of low dose DNA elicited Th1 cytokines and anti-envelope antibodies. Immunization with gp120 protein alone with or without Talabostat elicited lower Th1 and Th2 cytokine levels but comparable anti-gp120 antibodies to QS-21-formulated protein. Boosting of DNA-primed mice with gp120/Talabostat induced similar anti-gp120 antibody titers and slightly higher levels of Th1 and Th2 cytokines relative to QS-21-formulated protein. Induction of CD8(+) and CD4(+) T cells and functional CTL activity was noted. These results highlight the potential use of orally administered Talabostat for efficient protein boosting of antibody and T-cell responses primed by DNA.
authors.affiliation: Advanced BioScience Laboratories, Inc., 5510 Nicholson Lane, Kensington, MD 20895, USA.
authors.forename: Anthony D
authors.initials: AD
authors.lastname: Cristillo
authors.forename: Lindsey
authors.initials: L
authors.lastname: Galmin
authors.forename: Susana
authors.initials: S
authors.lastname: Restrepo
authors.forename: Lauren
authors.initials: L
authors.lastname: Hudacik
authors.forename: John
authors.initials: J
authors.lastname: Suschak
authors.forename: Brad
authors.initials: B
authors.lastname: Lewis
authors.forename: Ruxandra
authors.initials: R
authors.lastname: Draghia-Akli
authors.forename: Nazneen
authors.initials: N
authors.lastname: Aziz
authors.forename: Deborah
authors.initials: D
authors.lastname: Weiss
authors.forename: Phillip
authors.initials: P
authors.lastname: Markham
authors.forename: Ranajit
authors.initials: R
authors.lastname: Pal
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D000917:Antibody Formation; D001897:Boronic Acids / Q000008:administration & dosage*; D016207:Cytokines / Q000378:metabolism; D004279:DNA, Viral / Q000235:genetics; D004151:Dipeptides / Q000008:administration & dosage*; D018274:Electroporation; D005260:Female; D015699:HIV Envelope Protein gp120 / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D018417:Th1 Cells / Q000187:drug effects / Q000276:immunology; D018418:Th2 Cells / Q000187:drug effects / Q000276:immunology; D019444:Vaccines, DNA / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D001897:Boronic Acids; D016207:Cytokines; D004279:DNA, Viral; D004151:Dipeptides; D015699:HIV Envelope Protein gp120; D011994:Recombinant Proteins; D019444:Vaccines, DNA; C514044:talabostat